keyword
MENU ▼
Read by QxMD icon Read
search

Cancer hematology oncology

keyword
https://www.readbyqxmd.com/read/29142747/clinical-characteristics-of-critically-ill-cancer-patients-who-are-undergoing-isolated-limb-perfusion
#1
Silvio A Ñamendys-Silva, Arturo M Ruiz-Beltran, Mireya Barragán-Dessavre, Andoreni R Bautista-Ocampo, Abelardo Meneses-García, Octavio González-Chon, Angel Herrera-Gómez
The aim of the present study was to investigate the incidence of organ dysfunction, and to describe the clinical characteristics and intensive care unit (ICU) outcomes of critically ill cancer patients who were admitted to an oncological ICU during the isolated limb perfusion post-operative period. The present study was an observational investigation of 42 critically ill cancer patients who were admitted to the ICU of the Instituto Nacional de Cancerología, during the isolated limb perfusion post-operative period, between July 2010 and February 2016...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29142182/a-real-world-retrospective-cohort-study-of-combined-therapy-with-bevacizumab-and-paclitaxel-in-japanese-patients-with-metastatic-breast-cancer
#2
Hirofumi Yamada, Kenichi Inoue, Shigenori E Nagai, Maki Nakai, Fumio Arisawa, Hiroyuki Ueda, Tsuyoshi Saito, Jun Ninomiya, Toru Kuroda, Takashi Sakurai, Hitomi Kodama, Kei Kimizuka, Satoshi Hata, Toshihiro Kai, Masafumi Kurosumi
OBJECTIVE: Combined therapy with bevacizumab and paclitaxel (BP regimen) as a first-line treatment has proven highly effective with good tolerance for patients with metastatic breast cancer (MBC). The objective of this study was to examine the efficacy and safety of the BP regimen for Japanese patients with MBC in real-world clinical settings. METHODS: From June 2012 through May 2014, we recruited 94 patients at 10 medical institutions. The primary endpoint was time to treatment failure (TTF), and the secondary endpoints were overall survival (OS) and safety...
2017: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/29135093/evaluation-of-safety-of-bevacizumab-as-second-line-treatment-of-patients-with-metastatic-colorectal-cancer
#3
Vladimir Todorovic, Nada Cicmil Saric, Jadranka Lakicevic, Milan Sorat
PURPOSE: Bevacizumab is a relatively new monoclonal antibody introduced in the treatment of metastatic colorectal cancer (CRC). Since varied efficiency and adverse events of this drug were reported, the purpose of this study was to assess the safety of bevacizumab as second-line treatment of patients with metastatic CRC. METHODS: This observational, non-interventional study involved 35 patients with metastatic CRC treated with bevacizumab. Patients were from the Oncology Clinic, Clinical Centre of Montenegro...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29133515/-rather-one-more-chemo-than-one-less%C3%A2-oncologists-and-oncology-nurses-reasons-for-aggressive-treatment-of-young-adults-with-advanced-cancer
#4
Katsiaryna Laryionava, Pia Heußner, Wolfgang Hiddemann, Eva C Winkler
BACKGROUND: Empirical research demonstrates that there is a tendency to administer tumor-directed therapy to patients with advanced cancer close to death, especially if they are young. The aim of this qualitative study was to understand oncologists' treatment decisions and oncology nurses' perception of these decisions in young adult patients and to investigate the extent to which young age was a factor in cancer treatment decisions. MATERIALS AND METHODS: We conducted 29 face-to-face interviews with oncologists and oncology nurses at the Department of Hematology and Oncology at the University Hospital in Munich, Germany...
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29130003/spontaneous-tumor-lysis-syndrome-due-to-uterine-leiomyosarcoma-with-lung-metastases
#5
Vivek Alaigh, Debapriya Datta
Tumor lysis syndrome (TLS) is an oncologic emergency characterized by a combination of metabolic derangements (hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia) caused by rapid turnover from cell destruction in certain cancers. These metabolic derangements can lead to seizures, cardiac arrhythmias, renal failure, and death. TLS is usually seen after the initiation of chemotherapy for hematologic malignancies. TLS occurring spontaneously, without initiation of chemotherapy, is rare and its occurrence in solid tumors is rarer still...
2017: Case Reports in Critical Care
https://www.readbyqxmd.com/read/29121889/prevalence-and-associated-factors-of-medication-non-adherence-in-hematological-oncological-patients-in-their-home-situation
#6
Linda Bouwman, Corien M Eeltink, Otto Visser, Jeroen J W M Janssen, Jolanda M Maaskant
BACKGROUND: Medication non-adherence is associated with poor health outcomes and increased health care costs. Depending on definitions, reported non-adherence rates in cancer patients ranges between 16 and 100%, which illustrates a serious problem. In malignancy, non-adherence reduces chances of achievement of treatment response and may thereby lead to progression or even relapse. Except for Chronic Myeloid Leukemia (CML), the extent of non-adherence has not been investigated in hematological-oncological patients in an outpatient setting...
November 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29104344/validation-of-a-machine-learning-approach-for-venous-thromboembolism-risk-prediction-in-oncology
#7
Patrizia Ferroni, Fabio M Zanzotto, Noemi Scarpato, Silvia Riondino, Fiorella Guadagni, Mario Roselli
Using kernel machine learning (ML) and random optimization (RO) techniques, we recently developed a set of venous thromboembolism (VTE) risk predictors, which could be useful to devise a web interface for VTE risk stratification in chemotherapy-treated cancer patients. This study was designed to validate a model incorporating the two best predictors and to compare their combined performance with that of the currently recommended Khorana score (KS). Age, sex, tumor site/stage, hematological attributes, blood lipids, glycemic indexes, liver and kidney function, BMI, performance status, and supportive and anticancer drugs of 608 cancer outpatients were all entered in the model, with numerical attributes analyzed as continuous values...
2017: Disease Markers
https://www.readbyqxmd.com/read/29102390/comorbidities-clinical-features-and-prognostic-implications-of-cancer-patients-with-cerebrovascular-disease
#8
Bernardo Cacho-Díaz, Nydia A Lorenzana-Mendoza, Héctor Spínola-Maroño, Gervith Reyes-Soto, Carlos Cantú-Brito
PURPOSE: The objective of this study was to identify and describe the comorbidities, clinical features, and prognostic implications of cancer patients with cerebrovascular disease. MATERIALS AND METHODS: All patients with cerebrovascular disease (CVD) seen in the neuro-oncology unit at a cancer referral center from April 2010 to November 2016 were included; demographic, oncologic diagnosis, risk factors, and prognostic considerations were presented as well. RESULTS: We report on 256 patients with CVD and cancer, of whom 66% were women...
October 25, 2017: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/29098766/some-statistical-considerations-in-the-clinical-development-of-cancer-immunotherapies
#9
Bo Huang
Immuno-oncology has emerged as an exciting new approach to cancer treatment. Common immunotherapy approaches include cancer vaccine, effector cell therapy, and T-cell-stimulating antibody. Checkpoint inhibitors such as cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/L1 antagonists have shown promising results in multiple indications in solid tumors and hematology. However, the mechanisms of action of these novel drugs pose unique statistical challenges in the accurate evaluation of clinical safety and efficacy, including late-onset toxicity, dose optimization, evaluation of combination agents, pseudoprogression, and delayed and lasting clinical activity...
November 2, 2017: Pharmaceutical Statistics
https://www.readbyqxmd.com/read/29076761/cdk5-in-oncology-recent-advances-and-future-prospects
#10
Jimma Likisa Lenjisa, Solomon Tadesse, Nishat Zareen Khair, Malika Kumarasiri, Mingfeng Yu, Hugo Albrecht, Robert Milne, Shudong Wang
Selective abrogation of cyclin-dependent kinases (CDK) activity is a highly promising strategy in cancer treatment. The atypical CDK, CDK5 has long been known for its role in neurodegenerative diseases, and is becoming an attractive drug target for cancer therapy. Myriads of recent studies have uncovered that aberrant expression of CDK5 contributes to the oncogenic initiation and progression of multiple solid and hematological malignancies. CDK5 is also implicated in the regulation of cancer stem cell biology...
October 27, 2017: Future Medicinal Chemistry
https://www.readbyqxmd.com/read/29075104/risk-of-severe-hematologic-toxicities-in-cancer-patients-treated-with-parp-inhibitors-a-meta-analysis-of-randomized-controlled-trials
#11
Jian Xin Zhou, Li Jin Feng, Xi Zhang
PURPOSE: Hematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied. Therefore, we conducted a meta-analysis of published clinical trials to investigate the incidence and relative risks (RRs) of severe (high-grade) hematologic events in cancer patients treated with PARPis. METHODS: PubMed, Embase, and oncology conference proceedings were searched for relevant studies...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29072767/biocompatible-silver-gold-and-silver-gold-alloy-nanoparticles-for-enhanced-cancer-therapy-in-vitro-and-in-vivo-perspectives
#12
Thangavel Shanmugasundaram, Manikkam Radhakrishnan, Venugopal Gopikrishnan, Krishna Kadirvelu, Ramasamy Balagurunathan
The aims of nano oncology are to detect, target and treat cancer cells without any side effects. The present study describes the microbial synthesis of biocompatible nanoparticles of silver (AgNPs), gold (AuNPs) and their alloy (Ag/AuNPs) for hepatoprotective activity against diethylnitrosamine (DEN)-induced liver cancer in a Sprague Dawley (SD) rat model. The crystalline nature and physicochemical features of the nanoparticles were identified by Fourier transform infra-red (FT-IR) spectroscopy, X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), transmission electron microscopy (TEM) and selected area electron diffraction (SAED) analysis...
November 9, 2017: Nanoscale
https://www.readbyqxmd.com/read/29072402/outcomes-of-high-risk-patients-with-febrile-neutropenia-at-a-tertiary-care-center
#13
Asif Husain Osmani, Adnan Abdul Jabbar, Manesh Kumar Gangwani, Bilal Hassan
Fever during chemotherapy-induced neutropenia continues to be a major cause of morbidity and mortality in cancer patients. Mortality depends on the duration and degree of neutropenia, bacteremia, sepsis, performance status, comorbidities and other parameters. The highest mortality rates in cancer patients hospitalized with febrile neutropenia (FN) are observed in those with documented infection. The objectives of the study were to present available tools for risk assessment, to review pathogens causing infections in adult FN patients and to assess outcomes...
October 26, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29058129/does-grip-strength-decrease-in-the-very-early-stages-of-hematological-treatment
#14
C G C Teodozio, G V Chaves, I P Arcuri, F T Frajacomo
Muscle weakness in hematological cancer patients undergoing acute stages of treatment is an important concern and strong predictor of poor outcomes. However, evidence of strength loss in the very early stages of cancer treatment is not addressed. Here, we found that grip strength was compromised within the first 7 days of hematological treatment (- 2.3 kg, P = 0.002). These findings are novel in elucidating lower handgrip strength in the first week of hematological treatment and encourage additional research focusing on handgrip strength in oncology patients under initial high-dose chemotherapy routine...
October 23, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29056630/cancer-and-fertility
#15
Ana S Iltis
This symposium includes 12 personal narratives from individuals who have faced a cancer diagnosis-either their own or their child's-where the disease itself, or their treatment, threatened future fertility. Three additional stories are available in the online supplement. Three commentaries on these narratives are written by an expert in oncofertility, a healthcare ethicist, and a pediatrician completing a fellowship in hematology/oncology. The observations and insights these authors share underscore the importance of addressing fertility loss and preservation early in the cancer journey...
2017: Narrative Inquiry in Bioethics
https://www.readbyqxmd.com/read/29050107/-recommendations-for-the-diagnosis-and-treatment-of-rhabdomyosarcoma-in-chinese-children-and-adolescents-cccg-rms-2016
#16
(no author information available yet)
No abstract text is available yet for this article.
October 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/29037236/a-single-arm-phase-ii-study-of-nab-paclitaxel-for-patients-with-chemorefractory-non-small-cell-lung-cancer
#17
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
BACKGROUND: We aimed to evaluate the efficacy and safety of nab-paclitaxel in patients with refractory advanced non-small cell lung cancer who failed previous chemotherapy. METHODS: Patients were required to have an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received nab-paclitaxel, 100 mg/m(2) i.v. on days 1, 8, and 15 every 4 weeks. The primary endpoint was the overall response rate. Secondary endpoints were the progression-free survival time, overall survival, and the toxicity profile...
October 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29031507/-sport-coaching-for-psychological-and-social-recovery-after-hematological-cancer-an-innovative-perspective
#18
Sarah Calvin, Didier Blaise, Patrick Ben Soussan, Sarah Cuvelier, Nicolas Cicut, Laurence Caymaris, Yolande Arnault, Claude Onesta, Pierre Dantin, Patrice Viens
This study is a first step towards the transfer of knowledge and practices between psychological support and performance in elite sport and a patient's "social recovery" in oncology. This proposal brings together people engaged in a variety of healthcare and relationship support roles, and aims to set up a support system beyond the hospital context. It questions the ability of elite sport management and its main actors, the "Great Coaches", to contribute to the support of patients in cancer remission through an onco-coaching approach...
October 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29028642/-lost-to-follow-up-among-adult-cancer-survivors
#19
Amitoj Gill, Rohit Gosain, Shruti Bhandari, Rahul Gosain, Gurkirat Gill, Joseph Abraham, Kenneth Miller
BACKGROUND: Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to determine what proportion of cancer survivors are LFU at 5 years after treatment, the timing of LFU, and the characteristics of those who do not continue survivorship care. METHODS: Adult patients with cancer who were treated with chemotherapy at a large community teaching hospital in 2006 and 2007 were identified and linked with State tumor registry data...
October 12, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28978832/clinical-sequencing-in-leukemia-with-the-assistance-of-artificial-intelligence
#20
Arinobu Tojo
Next generation sequencing (NGS) of cancer genomes is now becoming a prerequisite for accurate diagnosis and proper treatment in clinical oncology. Because the genomic regions for NGS expand from a certain set of genes to the whole exome or whole genome, the resulting sequence data becomes incredibly enormous and makes it quite laborious to translate the genomic data into medicine, so-called annotation and curation. We organized a clinical sequencing team and established a bidirectional (bed-to-bench and bench-to-bed) system to integrate clinical and genomic data for hematological malignancies...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
keyword
keyword
73361
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"